Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials-Reference-Cited by-同舟云学术

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

Published:2019-08 Issue: Volume:117 Page:91-98
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Martín M.,Loibl S.,Hyslop T.,De la Haba-Rodríguez J.,Aktas B.,Cirrincione C.T.,Mehta K.,Barry W.T.,Morales S.,Carey L.A.,Garcia-Saenz J.A.,Partridge A.,Martinez-Jañez N.,Hahn O.,Winer E.,Guerrero-Zotano A.,Hudis C.,Casas M.,Rodriguez-Martin C.,Furlanetto J.,Carrasco E.,Dickler M.N.

Funder

National Cancer Institute of the National Institutes of Health

The Breast Cancer Research Foundation, Genentech

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors;Qu;Cancer Res,2008

2. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer;Foekens;Cancer Res,2001

3. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study;Martin;J Clin Oncol,2015

4. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (alliance);Dickler;J Clin Oncol,2016

5. The robust inference for the proportional hazards model;Lin DYW;J Am Stat Assoc,1989

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities;Biomedicine & Pharmacotherapy;2024-06

2. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF;European Journal of Pharmacology;2023-06

3. Targeting the formation of estrogens for treatment of hormone dependent diseases–current status;Frontiers in Pharmacology;2023-04-28

4. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer;CA: A Cancer Journal for Clinicians;2023-03-20

5. Novel therapeutics in low-grade serous ovarian cancer;International Journal of Gynecologic Cancer;2023-03